290 related articles for article (PubMed ID: 22689024)
1. [Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].
Araos R; García P; Chanqueo L; Labarca J
Rev Chilena Infectol; 2012 Apr; 29(2):127-31. PubMed ID: 22689024
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
Eisenstein BI; Oleson FB; Baltz RH
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
[TBL] [Abstract][Full Text] [Related]
3. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
Johnson A
Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
[TBL] [Abstract][Full Text] [Related]
5. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
11. [New drugs; daptomycin].
van Bronswijk H; Dubois EA; van Dissel JT; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2777-8. PubMed ID: 18232197
[TBL] [Abstract][Full Text] [Related]
12. [Daptomycin in diabetic patients].
Montejo M
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():54-8. PubMed ID: 22541977
[TBL] [Abstract][Full Text] [Related]
13. Future directions with daptomycin.
Livermore DM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii41-iii49. PubMed ID: 18829725
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009.
Utili R; Cogo A; Cristini F; Prisco V; Sagnelli E; Tascini C; Iacoboni C; Capone A; Gattuso G; Angarano G; Petrelli E; Grossi P; Bartezaghi M; Zagni E
J Chemother; 2012 Apr; 24(2):113-21. PubMed ID: 22546768
[TBL] [Abstract][Full Text] [Related]
17. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
Kern WV
Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
[TBL] [Abstract][Full Text] [Related]
19. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria].
Candel González FJ
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin: pharmacology and clinical use.
Kosmidis C; Levine DP
Expert Opin Pharmacother; 2010 Mar; 11(4):615-25. PubMed ID: 20163272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
